Table 1.
Patient demographics, diagnoses, and treatment regimens.
| Control group | Cannabis-first group | Oxaliplatin-first group | p-value | |
|---|---|---|---|---|
| No. | 265 | 116 | 132 | |
| Age, years, median | 64 | 62.5 | 61 | 0.18 |
| IQR (58, 72) | IQR (54.7, 70) | IQR (57, 70) | ||
| (27–90) | (24–80) | (26–84) | ||
| Gender | 0.510 | |||
| Male (%) | 139 (52.5) | 54 (46.6) | 70 (53.0) | |
| Female (%) | 126 (47.5) | 62 (53.4) | 62 (46.7) | |
| Diagnosis (%) | 0.3 | |||
| Colon | 155 (58.5) | 47 (40.5) | 62 (47) | |
| Upper GI | 39 (14.7) | 18 (15.5) | 19 (14.4) | |
| Pancreatic | 70 (26.4) | 47 (40.5) | 49 (37.1) | |
| Other | 1 (0.4) | 4 (3.44) | 2 (1.5) | |
| Metastatic disease | 168 (63.4) | 99 (85.3) | 104 (78.8) | <0.001 |
| Protocol Tx (%) | 0.001 | |||
| FLOX | 19 (7.2) | 3 (2.6) | 4 (3.0) | |
| FOLFIRINOX | 51 (19.2) | 38 (32.8) | 37 (28.0) | |
| FOLFOX | 195 (73.6) | 72 (62.1) | 91 (68.9) | |
| FOLFOXIRI | 0 (0.0) | 3 (2.6) | 0 (0.0) | |
| Cumulative Oxaliplatin dose (mg/m2, median) | 425 | 595 | 340 | <0.001 |
| IQR (170, 680) | IQR (417, 765) | IQR (195, 591) |
IQR, interquartile range, GI, gastrointestinal; NaN non-available; Tx, treatment.